Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 19.05%49.01M | 18.86%12.81M | 21.36%13.21M | 16.45%11.81M | 19.41%11.19M | 29.28%41.17M | 24.21%10.77M | 29.36%10.89M | 43.54%10.14M | 21.79%9.37M |
Operating revenue | 19.05%49.01M | 18.86%12.81M | 21.36%13.21M | 16.45%11.81M | 19.41%11.19M | 29.28%41.17M | 24.21%10.77M | 29.36%10.89M | 43.54%10.14M | 21.79%9.37M |
Cost of revenue | 8.07%26.37M | 11.10%6.76M | 10.82%6.9M | 6.52%6.31M | 3.81%6.41M | 19.04%24.4M | 8.96%6.08M | 9.53%6.23M | 34.20%5.92M | 28.06%6.17M |
Gross profit | 35.04%22.64M | 28.92%6.05M | 35.47%6.31M | 30.39%5.5M | 49.53%4.78M | 47.77%16.77M | 51.73%4.69M | 70.69%4.66M | 59.09%4.22M | 11.28%3.2M |
Operating expense | 6.25%13.25M | -26.93%3.47M | 29.10%3.39M | 27.88%3.39M | 22.79%2.99M | 47.17%12.47M | 109.85%4.75M | 25.06%2.63M | 29.53%2.65M | 18.32%2.44M |
Selling and administrative expenses | 6.25%13.25M | -26.93%3.47M | 29.10%3.39M | 27.88%3.39M | 22.79%2.99M | 47.17%12.47M | 109.85%4.75M | 25.06%2.63M | 29.53%2.65M | 18.32%2.44M |
Operating profit | 118.52%9.39M | 4,395.00%2.58M | 43.68%2.92M | 34.63%2.11M | 135.09%1.79M | 49.53%4.3M | -107.25%-60K | 222.70%2.03M | 159.54%1.57M | -6.51%761K |
Net non-operating interest income expense | 3,371.43%243K | 700.00%104K | 6,200.00%63K | 980.00%44K | 1,700.00%32K | 163.64%7K | 360.00%13K | 200.00%1K | -150.00%-5K | 33.33%-2K |
Total other finance cost | -3,371.43%-243K | -700.00%-104K | -6,200.00%-63K | -980.00%-44K | -1,700.00%-32K | -163.64%-7K | -360.00%-13K | -200.00%-1K | --5K | --2K |
Other net income (expense) | 46.81%138K | -23.00%77K | 100.00%24K | -122.73%-5K | 205.00%42K | 134.94%94K | 143.86%100K | 180.00%12K | 344.44%22K | -135.29%-40K |
Other non- operating income (expenses) | 46.81%138K | -23.00%77K | 100.00%24K | -122.73%-5K | 205.00%42K | 134.94%94K | 143.86%100K | 180.00%12K | 344.44%22K | -135.29%-40K |
Income before tax | 122.16%9.78M | 5,103.77%2.76M | 47.02%3.01M | 35.65%2.15M | 159.11%1.86M | 69.56%4.4M | -91.09%53K | 233.22%2.05M | 167.23%1.58M | -9.45%719K |
Income tax | 134.80%2.14M | 3,195.00%619K | 61.09%741K | 31.80%402K | 127.11%377K | 14.30%911K | -104.94%-20K | 314.41%460K | 187.74%305K | -5.14%166K |
Net income | 118.86%7.64M | 2,830.14%2.14M | 42.94%2.27M | 36.57%1.74M | 168.72%1.49M | 94.05%3.49M | -61.58%73K | 215.31%1.59M | 162.76%1.28M | -10.66%553K |
Net income continuous Operations | 118.86%7.64M | 2,830.14%2.14M | 42.94%2.27M | 36.57%1.74M | 168.72%1.49M | 94.05%3.49M | -61.58%73K | 215.31%1.59M | 162.76%1.28M | -10.66%553K |
Minority interest income | ||||||||||
Net income attributable to the parent company | 118.86%7.64M | 2,830.14%2.14M | 42.94%2.27M | 36.57%1.74M | 168.72%1.49M | 94.05%3.49M | -61.58%73K | 215.31%1.59M | 162.76%1.28M | -10.66%553K |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 118.86%7.64M | 2,830.14%2.14M | 42.94%2.27M | 36.57%1.74M | 168.72%1.49M | 94.05%3.49M | -61.58%73K | 215.31%1.59M | 162.76%1.28M | -10.66%553K |
Basic earnings per share | 115.50%2.78 | 3,700.00%0.76 | 38.98%0.82 | 36.17%0.64 | 161.90%0.55 | 92.54%1.29 | -71.43%0.02 | 210.53%0.59 | 161.38%0.47 | 82.88%0.21 |
Diluted earnings per share | 107.03%2.65 | 3,550.00%0.73 | 42.11%0.81 | 34.04%0.63 | 165.00%0.53 | 91.04%1.28 | -71.43%0.02 | 200.00%0.57 | 161.38%0.47 | 74.17%0.2 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |